At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 374 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Laquinimod 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Nov 6, 2014·Updated Mar 10, 2022
In Brief
A Phase 2 clinical trial evaluating Placebo and Laquinimod for Primary Progressive Multiple Sclerosis. Completed, enrolled 374 participants across 99 sites in 10 countries.
Detailed Summary
This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Progressive Multiple Sclerosis
CountriesCanada, Germany, Italy, Netherlands, Poland, Russia, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartJan 2015
Primary CompletionMay 2017
Study CompletionOct 2017
TodayJul 2026
First PostedNov 6, 2014
Enrollment StartJan 12, 2015
Primary CompletionMay 4, 2017
Study CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.7 years ago
Interventions
Placebodrug
Placebo
Laquinimoddrug
Laquinimod capsules in 0.5 mg and 0.6 mg strengths
Placebodrug
Placebo capsules